Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) has seen a massive down tick in the past few trading sessions, and we believe that this downward trajectory might continue for the stock and may lead it to lower levels. Short term traders can short the stock at current levels with a tight stop loss at $11 for targets of $8 or lower. Positional traders can also take short positions in the stock as we believe that the stock can head lower to levels of $6 and $5 in the medium term, and they should maintain a tight stop loss of $11 on a weekly closing basis. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), shares after opening at $9.73 moved to $9.73 on last trade day and at the end of the day closed at $8.89. Company price to cash ratio as 905.89. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), showed a negative weekly performance of 6.62%.
Mediabistro Inc (NASDAQ:MBIS), announced the speakers for the Inside 3D Printing Conference and Expo with Maker Summit & Pavilion, taking place in South Korea June 12-13, 2014. Inside 3D Printing, which held successful events in Berlin and New York earlier this year, will be the first major 3D printing and additive manufacturing trade show in South Korea. Mediabistro Inc (NASDAQ:MBIS), shares fell 5.74% in last trading session and ended the day on $1.15. Mediabistro Inc (NASDAQ:MBIS), return on equity ratio is recorded as -198.80% and its return on assets is -52.50%. Mediabistro Inc (NASDAQ:MBIS), yearly performance is -4.96%.
For the fourth quarter of 2013, Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), reported a net loss attributable to common stockholders of $18.7 million, or $4.98 per share, basic and diluted, compared with a net loss attributable to common stockholders for the fourth quarter of 2012 of $6.8 million, or $2.83 per share, basic and diluted. For the year ended December 31, 2013, Ultragenyx reported a net loss attributable to common stockholders of $50.3 million, or $14.87 per share, basic and diluted, compared with a net loss attributable to common stockholders for the year ended December 31, 2012 of $19.6 million, or $14.20 per share, basic and diluted. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), shares moved down 9.36% in last trading session and was closed at $45.22, while trading in range of $ 44.17 – 49.91. Retail Opportunity Investments Corp (NASDAQ:ROIC), year to date (YTD) performance is 7.03%.
TearLab Corp (NASDAQ:TEAR), expects to announce its Q1 2014 financial results after market closes on Thursday May 8, 2014. TearLab is pleased to invite all willing participants in a conference call during which time financial results will be discussed. TearLab Corp (NASDAQ:TEAR), weekly performance is -20.57%. On last trading day company shares ended up $4.98. TearLab Corp (NASDAQ:TEAR), distance from 50-day simple moving average (SMA50) is -28.25%. Analysts mean target Price for the company is $12.40.